Searle Company Ltd · PSX:SEARL
Searle — The Searle Company — Investor Presentation (November 2025)
19 slides from Searle's investor presentation, November 2025
Slide 1: The Searle Company Limited Corporate Briefing Session – FY 2025
The Searle Company Limited Corporate Briefing Session – FY 2025
Slide 2: International Brands Private Limited
International Brands Private Limited effective holding Status 1 The Searle Company Limited 50.2% Listed 2 IBL HealthCare Limited 37.4% Listed 3 Searle Biosciences Private Limited 50.2% Unlisted 4 Nextar Pharma Private Limited 43.8% Unlisted 5 Searle Laboratories Private Limited 50.2% Unlisted Pharma
Slide 3: Subsidiaries of The Searle Company Limited
Subsidiaries of The Searle Company Limited Holding Direct subsidiaries Holding Indirect subsidiaries The Searle Company limited 74.2% IBL HealthCare Limited 100.0% Searle Biosciences Private Limited 87.2% Nextar Pharma Private Limited 100.0% Searle Laboratories Private Limited 100.0% Searle Pharmace
Slide 4: Company information
Company information Human resource & remuneration Board of directors Audit Committee Committee Mr. Adnan Asdar Ali Chairman Ms. Shaista Khaliq Rehman Chairperson Mr. Zubair Haider Shaikh Chairperson Mr. Tahir Ahmed Chief Executive Officer Mr. Adnan Asdar Ali Member Ms. Shaista Khaliq Rehman Member M
Slide 5: Our Core Values
Our Core Values Excellence Passion • Takes ownership of current role and • Source of energy in the workplace beyond • Demonstrates entrepreneurial drive • Delivers quality work • Shows grit • Strives for continuous improvement • Collaborates Selflessly • Creates transparency • Behaves Respectfully •
Slide 6: Global Overview - 2025
GLOBAL OVERVIEW - 2025 Global Pharmaceutical Market – 2025 Outlook Size: ~USD 1.65–1.75 trillion in 2024–25. Growth: Stable 5% CAGR projected to 2030 (ex-COVID effects). Regional Mix: • North America: ~50–55% of sales (largest share, US-driven). • Europe: ~22–23%. • Asia-Pacific: Rapid expansion (Ch
Slide 7: Pharmaceutical Industry Overview
PHARMACEUTICAL INDUSTRY OVERVIEW The global pharmaceutical Pakistan pharmaceutical industry market size is USD 1.7 size is USD 3.7 billion which is trillion approximately 0.2% of global market • Global pharmaceutical industry is expected to grow with Compound Annual Growth Rate (CAGR) of 5-6%. PKR b
Slide 8: Footprint
Footprint Second largest Six brands crossed PKR 1 No.1 in the following therapeutic categories: pharmaceutical company billion sales per annum 1 of Pakistan in terms of • Cardiovascular units sold • Gynae • Cough Suppressant No.2 in the following therapeutic categories: Eight brands crossed PKR More
Slide 9: Corporate Achievements and Recognitions
Corporate Achievements and Recognitions For the Year 2025, TSCL takes pride in their achievements towards to the service of mankind - creating opportunities and advantages for all individuals. TSCL has tiredly worked in various sectors, enforcing their Corporate Social Responsibility. Searle was ran
Slide 10: Product categories & therapeutic areas
Product categories & therapeutic areas Categories Therapeutic areas Pharmaceuticals Searle is leading in terms of derived market, having 89% of Biopharmaceuticals presence in all pharmaceutical categories Nutraceuticals Nutrition 1. Allergy / Cough / Cold 9. Neurology / Psychiatry Consumer 2. Analge
Slide 11: Leading brands in their therapeutic category
Leading brands in their therapeutic category Cough Hydryllin Muscle Relaxant Nuberol ORS Peditral Extor, Spiromide, Byscard Cardiovascular Tramal, Rotec Analgesic Gravinate, Lomotil, Selanz Gastrointestinal
Slide 12: Our partners
Our partners SS = ae S255 QZ CSL Vifor AstrazZ CHEMic “strazenec Nests <— MISDP => reckritt ee. > Santen BAUSCH+LOMB | es | a E— “~7 2d wes SE xcnicle ---- rPHARNA MmAbxience Rere’s to life Le ee i) Mea¥ehnsor == Gador BS EB 2Z5 2D riNnCciple FP tatannaw Pour HANSEN Poe Vb os i ORGANON Regen B<<_ fe
Slide 13: Exports
Exports Afghanistan Cambodia Kenya Mauritius Export contributes around 11% towards the total revenue of the company. Searle is the second largest pharmaceutical exporter of Pakistan. Myanmar Sri Lanka Philippines Maldives Currently operating in 12 countries and expanding. Uganda Vietnam Laos Oman
Slide 14: Our production facilities
Our production facilities The production is spread over 6 manufacturing facility, engaged in producing pharmaceutical, biopharmaceutical, nutraceutical, nutrition and consumer products. Out of 6, 3 facilities are located in Karachi while 3 in Lahore. The installed capacity and utilisation is as foll
Slide 15: Drug Pricing Policy
Drug Pricing Policy The MRPs of drugs can be adjusted annually based on the Consumer Price Index (CPI) of the preceding financial year, • Essential drugs allowed an increase up to 3.14% and for Low pricing drug is 4.49% • However, other than essential drugs have been deregulated since February 2024.
Slide 16: Corporate Social Responsibility
Corporate Social Responsibility Considering the importance of education and believing it to be a right of every citizen, Searle supports The Citizens Foundation to help them achieve the cause, empowering children to become agents of positive change. Continuing with our philosophy of being a socially
Slide 17: TSCL P&L Statement – Last 6 years (Rs in '000s)
TSCL P&L Statement – Last 6 years (Rs in ‘000s) Searle P&L statement - Last 6 years (PKR '000s) Descriptions FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Sales – Net 24,773,372 25,827,210 21,641,282 17,737,282 16,569,596 16,567,219 Cost of Sales (12,185,186) (13,270,821) (12,097,595) (9,089,252)
Slide 18: TSCL P&L Statement – Q1 FY 2026 (Rs in '000s)
TSCL P&L Statement – Q1 FY 2026 (Rs in ‘000s) Searle P&L statement - Q1 FY 2026 (PKR '000s) Descriptions Q1 – FY 2025 Q1 – FY 2024 Growth Sales – Net 8,567,319 6,677,620 28% Cost of Sales (3,777,796) (3,616,743) 4% Gross Profit 4,789,523 3,060,877 56% Administrative and general expenses (414,016) (3
Slide 19: TSCL Balance Sheet – Last 6 years (Rs in '000s)
TSCL Balance Sheet – Last 6 years (Rs in ‘000s) Balance sheet FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 Balance sheet FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 Non-Current Assets 7,858,418 25,685,689 28,366,816 28,333,701 20,960,333 21,497,681 Equity 16,870,818 24,487,654 27,037,458 27,6
The Searle Company — Investor Presentation (November 2025) on 6ix